Surgical resection versus thermal ablation after intra-arterial conversion therapy for unresectable hepatocellular carcinoma: a multicenter retrospective one as per the STROBE guidelines

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi: 10.1016/S0140-6736(18)30010-2.
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750. doi: 10.1002/hep.29913.
   PubMed Web of Science ®Google Scholar
• Park J-W, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver Int. 2015;35(9):2155–2166. doi: 10.1111/liv.12818.
   PubMed Web of Science ®Google Scholar
• Vitale A, Trevisani F, Farinati F, et al. Treatment of hepatocellular carcinoma in the precision medicine era: from treatment stage migration to therapeutic hierarchy. Hepatology. 2020;72(6):2206–2218. doi: 10.1002/hep.31187.
   PubMed Web of Science ®Google Scholar
• Zhu X-D, Huang C, Shen Y-H, et al. Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations. Liver Cancer. 2021;10(4):320–329. doi: 10.1159/000514313.
   PubMed Web of Science ®Google Scholar
• Xie DY, Ren ZG, Zhou J, et al. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9(4):452–463. doi: 10.21037/hbsn-20-480.
   PubMed Web of Science ®Google Scholar
• Zhang W, Tong S, Hu B, et al. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial. J Immunother Cancer. 2023;11(9):e007366. doi: 10.1136/jitc-2023-007366.
   PubMed Web of Science ®Google Scholar
• Zhu H-D, Li H-L, Huang M-S, et al. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Ther. 2023;8(1):58. doi: 10.1038/s41392-022-01235-0.
   PubMed Web of Science ®Google Scholar
• Deng M, Cai H, He B, et al. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization, potential conversion therapies for single huge hepatocellular carcinoma: a retrospective comparison study. Int J Surg. 2023;109(11):3303–3311. doi: 10.1097/JS9.0000000000000654.
   PubMed Web of Science ®Google Scholar
• Benson AB, D’Angelica MI, Abrams T, et al. NCCN Guidelines® Insights: biliary Tract Cancers, Version 2.2023. J Natl Compr Canc Netw. 2023;21(7):694–704. doi: 10.6004/jnccn.2023.0035.
   PubMed Web of Science ®Google Scholar
• Kuo Y-H, Lu S-N, Chen Y-Y, et al. Real-world lenvatinib versus sorafenib in patients with advanced hepatocellular carcinoma: a propensity score matching analysis. Front Oncol. 2021;11:823960. doi: 10.3389/fonc.2021.737767.
   PubMed Web of Science ®Google Scholar
• Sidaway P. FOLFOX-HAIC active in large HCC. Nat Rev Clin Oncol. 2022;19(1):5–5. doi: 10.1038/s41571-021-00577-y.
   PubMed Web of Science ®Google Scholar
• Salem R. Hepatic arterial infusion chemotherapy for large hepatocellular carcinoma: ready for prime time. J Clin Oncol. 2022;40(2):118–119. doi: 10.1200/JCO.21.02392.
   PubMed Web of Science ®Google Scholar
• Li Q-J, He M-K, Chen H-W, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial. J Clin Oncol. 2022;40(2):150–160. doi: 10.1200/JCO.21.00608.
   PubMed Web of Science ®Google Scholar
• Lyu N, Kong Y, Mu L, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2018;69(1):60–69. doi: 10.1016/j.jhep.2018.02.008.
   PubMed Web of Science ®Google Scholar
• Peng Z, Fan W, Zhu B, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH). J Clin Oncol. 2023;41(1):117–127. doi: 10.1200/JCO.22.00392.
   PubMed Web of Science ®Google Scholar
• Xia D, Bai W, Wang E, et al. Lenvatinib with or without concurrent drug-eluting beads transarterial chemoembolization in patients with unresectable, advanced hepatocellular carcinoma: a real-world, multicenter, retrospective study. Liver Cancer. 2022;11(4):368–382. doi: 10.1159/000523849.
   PubMed Web of Science ®Google Scholar
• Lai Z, He M, Bu X, et al. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: a biomolecular exploratory, phase II trial. Eur J Cancer. 2022;174:68–77. doi: 10.1016/j.ejca.2022.07.005.
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi: 10.1002/hep.29086.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.
   PubMed Web of Science ®Google Scholar
• Yu H, Bai Y, Xie X, et al. RECIST 1.1 versus mRECIST for assessment of tumor response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis. BMJ Open. 2022;12(6):e052294. doi: 10.1136/bmjopen-2021-052294.
   PubMed Web of Science ®Google Scholar
• Kuroda H, Oikawa T, Ninomiya M, et al. Objective response by mRECIST to initial lenvatinib therapy is an independent factor contributing to deep response in hepatocellular carcinoma treated with lenvatinib-transcatheter arterial chemoembolization sequential therapy. Liver Cancer. 2022;11(4):383–396. doi: 10.1159/000522424.
   PubMed Web of Science ®Google Scholar
• Patel IJ, Rahim S, Davidson JC, et al. Society of Interventional Radiology Consensus guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions – part II: recommendations: endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe. J Vasc Interv Radiol. 2019;30(8):1168–1184.e1. doi: 10.1016/j.jvir.2019.04.017.
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi: 10.1056/NEJMoa1915745.
   PubMed Web of Science ®Google Scholar
• Shi F, Wu M, Lian S-S, et al. Radiofrequency ablation following downstaging of hepatocellular carcinoma by using transarterial chemoembolization: long-term outcomes. Radiology. 2019;293(3):707–715. doi: 10.1148/radiol.2019181991.
   PubMed Web of Science ®Google Scholar
• Shi F, Lian S, Mai Q, et al. Microwave ablation after downstaging of hepatocellular carcinoma: outcome was similar to tumor within Milan criteria. Eur Radiol. 2020;30(5):2454–2462. doi: 10.1007/s00330-019-06604-y.
   PubMed Web of Science ®Google Scholar
• Li S-H, Mei J, Cheng Y, et al. Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion: a multicenter, phase III, randomized study. J Clin Oncol. 2023;41(10):1898–1908. doi: 10.1200/JCO.22.01142.
   PubMed Web of Science ®Google Scholar
• Voron T, Colussi O, Marcheteau E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015;212(2):139–148. doi: 10.1084/jem.20140559.
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang R, Deng J, et al. Construction of TME and Identification of crosstalk between malignant cells and macrophages by SPP1 in hepatocellular carcinoma. Cancer Immunol Immunother. 2022;71(1):121–136. doi: 10.1007/s00262-021-02967-8.
   PubMed Web of Science ®Google Scholar
• Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–550. doi: 10.1038/s41591-018-0014-x.
   PubMed Web of Science ®Google Scholar
• Fukuda H, Numata K, Moriya S, et al. Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation–propensity score matching analysis. Radiology. 2014;272(2):598–604. doi: 10.1148/radiol.14131640.
   PubMed Web of Science ®Google Scholar